Limits...
Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells.

Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T - Br. J. Cancer (2002)

Bottom Line: We found that cimetidine treatment was particularly effective in patients whose tumour had higher sL(x) and sL(a) antigen levels.In contrast, in the group of patients with no or low levels CSLEX staining, cimetidine did not show significant beneficial effect (the 10-year survival rate of the cimetidine group was 70.0% and that of control group was 85.7% (P=n.s.)).These results clearly indicate that cimetidine treatment dramatically improved survival in colorectal cancer patients with tumour cells expressing high levels of sL(x) and sL(a).

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Second Teaching Hospital, School of Medicine, Fujita Health University, 3-6-10 Otohbashi, Nakagawa-ku, Nagoya 454-8509, Japan. smatsumo@fujita-hu.ac.jp

Show MeSH

Related in: MedlinePlus

Effect of cimetidine on the survival of patients with colorectal cancer according to the Dukes classification. Dukes A and B, localized cancer limited to mucosa and submucosa (A) and extending through serosa without lymph node metastasis (B). Dukes C, cancers involving regional lymph nodes. Note that the beneficial effects of cimetidine were greater in patients with Dukes C: the cumulative 10-year survival rate of the cimetidine group (n=13) was 84.6%, whereas that of control group (n=13) was 23.1% (P=0.0016 by log rank test and P=0.0026 by generalized Wilcoxon test).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2375187&req=5

fig2: Effect of cimetidine on the survival of patients with colorectal cancer according to the Dukes classification. Dukes A and B, localized cancer limited to mucosa and submucosa (A) and extending through serosa without lymph node metastasis (B). Dukes C, cancers involving regional lymph nodes. Note that the beneficial effects of cimetidine were greater in patients with Dukes C: the cumulative 10-year survival rate of the cimetidine group (n=13) was 84.6%, whereas that of control group (n=13) was 23.1% (P=0.0016 by log rank test and P=0.0026 by generalized Wilcoxon test).

Mentions: We then evaluated the effects of cimetidine according to the clinical stage of colorectal cancer. As shown in Figure 2Figure 2


Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells.

Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T - Br. J. Cancer (2002)

Effect of cimetidine on the survival of patients with colorectal cancer according to the Dukes classification. Dukes A and B, localized cancer limited to mucosa and submucosa (A) and extending through serosa without lymph node metastasis (B). Dukes C, cancers involving regional lymph nodes. Note that the beneficial effects of cimetidine were greater in patients with Dukes C: the cumulative 10-year survival rate of the cimetidine group (n=13) was 84.6%, whereas that of control group (n=13) was 23.1% (P=0.0016 by log rank test and P=0.0026 by generalized Wilcoxon test).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2375187&req=5

fig2: Effect of cimetidine on the survival of patients with colorectal cancer according to the Dukes classification. Dukes A and B, localized cancer limited to mucosa and submucosa (A) and extending through serosa without lymph node metastasis (B). Dukes C, cancers involving regional lymph nodes. Note that the beneficial effects of cimetidine were greater in patients with Dukes C: the cumulative 10-year survival rate of the cimetidine group (n=13) was 84.6%, whereas that of control group (n=13) was 23.1% (P=0.0016 by log rank test and P=0.0026 by generalized Wilcoxon test).
Mentions: We then evaluated the effects of cimetidine according to the clinical stage of colorectal cancer. As shown in Figure 2Figure 2

Bottom Line: We found that cimetidine treatment was particularly effective in patients whose tumour had higher sL(x) and sL(a) antigen levels.In contrast, in the group of patients with no or low levels CSLEX staining, cimetidine did not show significant beneficial effect (the 10-year survival rate of the cimetidine group was 70.0% and that of control group was 85.7% (P=n.s.)).These results clearly indicate that cimetidine treatment dramatically improved survival in colorectal cancer patients with tumour cells expressing high levels of sL(x) and sL(a).

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Second Teaching Hospital, School of Medicine, Fujita Health University, 3-6-10 Otohbashi, Nakagawa-ku, Nagoya 454-8509, Japan. smatsumo@fujita-hu.ac.jp

Show MeSH
Related in: MedlinePlus